Company Overview and News

Mohamed Al Amin steps down as Nylex chairman, Ancom director

2018-08-03 theedgemarkets
KUALA LUMPUR (August 3): Nylex (Malaysia) Bhd executive chairman Tan Sri Mohamed Al Amin Abdul Majid has resigned, citing other commitments.
5049 BSMAF 1818

Country View takes over Iskandar Puteri plot on June 29

2018-06-27 theedgemarkets
PETALING JAYA (June 27): Country View Bhd will take delivery of vacant possession of 163.9 acres in Iskandar Puteri, Johor on June 29, based on a supplemental agreement with UEM Sunrise Bhd. The handover will commence even if the acquisition balance sum is pending full payment.
5148 5049 BSMAF 1818

Country View enters supplemental deal with UEM Sunrise

In a filing with Bursa Malaysia, Country View said that the acquisition’s balance sum would be paid to BNDSB by June 29, which is a period not later than eight months from the day the acquisition agreement was signed. The acquisition balance sum of RM279mil will be paid in two tranches.
5148 5049 BSMAF 1818

Last gasp for hog farm suit: 'We don't want to be hostages'

BERWICK, Pa. (AP) — When the wind blows a certain way, residents know to head inside. Quickly. They claim the stench from an industrial hog farm on the edge of town is unbearable.

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...